These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 22214393)

  • 61. Disease progression and costs of care in Alzheimer's disease patients treated with donepezil: a longitudinal naturalistic cohort.
    Gustavsson A; Jönsson L; Parmler J; Andreasen N; Wattmo C; Wallin ÅK; Minthon L
    Eur J Health Econ; 2012 Oct; 13(5):561-8. PubMed ID: 21822729
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors.
    Tayeb HO; Yang HD; Price BH; Tarazi FI
    Pharmacol Ther; 2012 Apr; 134(1):8-25. PubMed ID: 22198801
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil.
    Weycker D; Taneja C; Edelsberg J; Erder MH; Schmitt FA; Setyawan J; Oster G
    Curr Med Res Opin; 2007 May; 23(5):1187-97. PubMed ID: 17519086
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cholinesterase inhibitor and N-methyl-D-aspartic acid receptor antagonist use in older adults with end-stage dementia: a survey of hospice medical directors.
    Shega JW; Ellner L; Lau DT; Maxwell TL
    J Palliat Med; 2009 Sep; 12(9):779-83. PubMed ID: 19622011
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Long-term cost-effectiveness of donepezil for the treatment of Alzheimer's disease.
    Teipel SJ; Ewers M; Reisig V; Schweikert B; Hampel H; Happich M
    Eur Arch Psychiatry Clin Neurosci; 2007 Sep; 257(6):330-6. PubMed ID: 17404699
    [TBL] [Abstract][Full Text] [Related]  

  • 66. 2021 Alzheimer's disease facts and figures.
    Alzheimers Dement; 2021 Mar; 17(3):327-406. PubMed ID: 33756057
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Multiple target-based combination therapy of galantamine, memantine and lycopene for the possible treatment of Alzheimer's disease.
    Vishwas S; Awasthi A; Corrie L; Kumar Singh S; Gulati M
    Med Hypotheses; 2020 Oct; 143():109879. PubMed ID: 32474382
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Prescribing trends in cognition enhancing drugs in Australia.
    Hollingworth SA; Byrne GJ
    Int Psychogeriatr; 2011 Mar; 23(2):238-45. PubMed ID: 20670461
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Comparative cardiovascular safety of dementia medications: a cross-national study.
    Fosbøl EL; Peterson ED; Holm E; Gislason GH; Zhang Y; Curtis LH; Køber L; Iwata I; Torp-Pedersen C; Setoguchi S
    J Am Geriatr Soc; 2012 Dec; 60(12):2283-9. PubMed ID: 23176182
    [TBL] [Abstract][Full Text] [Related]  

  • 70. 2024 Alzheimer's disease facts and figures.
    Alzheimers Dement; 2024 May; 20(5):3708-3821. PubMed ID: 38689398
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The economic benefits of acetylcholinesterase inhibitors for patients with Alzheimer disease and associated dementias.
    Fillit H; Hill J
    Alzheimer Dis Assoc Disord; 2004; 18 Suppl 1():S24-9. PubMed ID: 15249845
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Assessment of Health Economics in Alzheimer's Disease (AHEAD): treatment with galantamine in Sweden.
    Garfield FB; Getsios D; Caro JJ; Wimo A; Winblad B
    Pharmacoeconomics; 2002; 20(9):629-37. PubMed ID: 12141890
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Economic evaluation of the impact of memantine on time to nursing home admission in the treatment of Alzheimer disease.
    Lachaine J; Beauchemin C; Legault M; Bineau S
    Can J Psychiatry; 2011 Oct; 56(10):596-604. PubMed ID: 22014692
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic model.
    Hyde C; Peters J; Bond M; Rogers G; Hoyle M; Anderson R; Jeffreys M; Davis S; Thokala P; Moxham T
    Age Ageing; 2013 Jan; 42(1):14-20. PubMed ID: 23179169
    [TBL] [Abstract][Full Text] [Related]  

  • 75. 2023 Alzheimer's disease facts and figures.
    Alzheimers Dement; 2023 Apr; 19(4):1598-1695. PubMed ID: 36918389
    [TBL] [Abstract][Full Text] [Related]  

  • 76. First International Pharmacoeconomic Conference on Alzheimer's Disease: report and summary.
    Whitehouse PJ; Winblad B; Shostak D; Bhattacharjya A; Brod M; Brodaty H; Dor A; Feldman H; Forette F; Gauthier S; Hay J; Henke C; Hill S; Mastey V; Neumann P; O'Brien B; Pugner K; Sano M; Sawada T; Stone R; Wimo A
    Alzheimer Dis Assoc Disord; 1998 Dec; 12(4):266-80. PubMed ID: 9876955
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effectiveness and cost-effectiveness of the pharmacological treatment of Alzheimer's disease and vascular dementia.
    Versijpt J
    J Alzheimers Dis; 2014; 42 Suppl 3():S19-25. PubMed ID: 25061049
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Modelling disease progression in Alzheimer's disease: a review of modelling methods used for cost-effectiveness analysis.
    Green C
    Pharmacoeconomics; 2007; 25(9):735-50. PubMed ID: 17803333
    [TBL] [Abstract][Full Text] [Related]  

  • 79. 2022 Alzheimer's disease facts and figures.
    Alzheimers Dement; 2022 Apr; 18(4):700-789. PubMed ID: 35289055
    [TBL] [Abstract][Full Text] [Related]  

  • 80. 2014 Alzheimer's disease facts and figures.
    Alzheimer's Association
    Alzheimers Dement; 2014 Mar; 10(2):e47-92. PubMed ID: 24818261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.